Ind-Swift Laboratories Q2 FY27 Standalone Net Profit at ₹31.03 Crore, up 252%
Ind-Swift Laboratories reported a standalone net profit of ₹31.03 Crore for Q2 FY27, a 252% increase from ₹8.76 Crore in Q2 FY26. Standalone revenue rose to ₹234.89 Crore from ₹156.43 Crore. The Board approved these results on October 29, 2026.
The significant year-on-year growth in profit and revenue is a material development that is likely to impact investor sentiment and the company's stock price.
The company reported a substantial increase in net profit and revenue for the quarter compared to the previous year, indicating strong financial performance.
Ind-Swift Laboratories Limited announced its financial results for the quarter and six months ended September 30, 2026. The Board of Directors, in a meeting held on October 29, 2026, approved the standalone and consolidated un-audited financial results.
For the quarter ended September 30, 2026, the company reported a standalone net profit of ₹31.03 Crore, a significant increase from ₹8.76 Crore in the corresponding quarter of the previous year. The EBITDA for the quarter stood at ₹42.33 Crore, compared to ₹8.55 Crore in the same period last year.
The company's revenue from operations for the standalone segment was ₹234.89 Crore for the quarter, an increase from ₹156.43 Crore in the same period last year. The consolidated revenue from operations was ₹240.46 Crore for the quarter, up from ₹158.64 Crore in the prior year's quarter.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The statutory auditors have issued unqualified limited review reports for both standalone and consolidated results.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.